News

Regeneron announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.

Timing of type 2 diabetes or hypertension diagnosis may impact the risk of primary open-angle glaucoma.

Craig Morgan, MD, and Eye Consultants of Huntington, West Virginia, paid $907,074.64 to resolve allegations that they submitted false claims to Medicare and Medicaid, the U.S. Attorney’s Office for the Southern District of West Virginia reported.

The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.

If approved, TP-03 may offer treatment for millions of patients with Demodex blepharitis. TP-03 is now also being studied for the treatment of Meibomian Gland Disease in patients with Demodex mites.

According to the National Institutes of Health, the therapy was derived from the patient’s blood by converting blood cells to iPS cells which were then programmed to become retinal pigment epithelial cells, which were surgically implanted as a patch of tissue.

GATHER2 met its prespecified primary endpoint of mean rate of growth (slope) in GA area at 12 months with statistical significance and a favorable safety profile. With this data in hand, Iveric Bio is working to submit a New Drug Application for Zimura to the FDA by the end of the first quarter of next year.

According to a presentation by the company at the 22nd EURETINA World Congress in Hamburg, Germany, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.

A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction.

According to an OHSA investigator, a study shows changes in patient volume, billing after private equity firms acquire physician practices.

Surveys have found that burnout among physicians who deliver “primary care” is so bad that 20% of them intend to stop practicing.

A study detailed at the 22nd EURETINA Congress in Hamburg, Germany, documented a spectrum of manifestations following COVID-19 infections in an otherwise immunocompetent patient presenting at a tertiary care center.

Researchers have found that social media use among physicians jumped during the COVID-19 pandemic, but the role it plays in networking, mentorship and support among ophthalmologists remains unknown.

According to the company, the fully connected environment, digital technologies and artificial intelligence tools enable optimization of patient care.

At the 22nd EURETINA World Congress in Hamburg, Germany,Isabelle Audo, MD, reported that voretigene neparvovec used to treat patients with a RPE65-related inherited retinal dystrophy, showed good safety and efficacy at the 1-year time point of the LIGHT Study.

According to researchers, findings could lead to new screening protocols to catch glaucoma early and preserve vision.

Bausch + Lomb expects to begin the distribution of the intraocular dyes in all EU countries, with the exception of Italy, during the first half of 2023. Bausch + Lomb and Alfa Instruments are also in the process of exploring regulatory requirements and approvals of the surgical dyes in other markets.

David J. Calkins, PhD, is being recognized for his groundbreaking contributions to the field of vision research.

The multi-center, international clinical study is designed to assess the safety and efficacy of novel investigational low-dose atropine eye drops in children 3-17 years old with myopia.

Product is forging a future in ocular regenerative procedures

ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases.

The first cases in the United States using the company’s suprachoroidal technology were performed earlier this month, and long-term clinical outcomes will be presented at the annual meeting of the American Academy of Ophthalmology in Chicago, starting Sept. 30.

Researchers at the University of Bonn are evaluating a new imaging technique for the diagnosis of posterior uveitis.

The 22nd European Society of Retina Specialists Congress kicks off Thursday at the Congress Centre Hamburg in Hamburg, Germany.

The debate continues about the protective effect of eyeglasses against contracting the COVID-19 virus. Researchers from Denmark reported that their results were inconclusive regarding whether wearing eyeglasses is linked with a decreased risk of COVID-19 infections.

The American Academy of Ophthalmology annual meeting is coming to Chicago, Illinois from September 30 to October 3, featuring Subspecialty Days and a virtual component. The event will be held at Chicago’s McCormick Place, billed as the largest convention center in North America and located on the shore of Lake Michigan.

The company has filed an ophthalmic IND submission for the first treatment of ocular conditions associated with DNA damage.